Style | Citing Format |
---|---|
MLA | Hashemi ZS, et al.. "Novel Delivery of Sorafenib by Natural Killer Cell-Derived Exosomes-Enhanced Apoptosis in Triple-Negative Breast Cancer." Nanomedicine, vol. 18, no. 5, 2023, pp. 437-453. |
APA | Hashemi ZS, Ghavami M, Kiaie SH, Mohammadi F, Barough MS, Khalili S, Hosseinifarjam Z, Mossahebimohammadi M, Sheidary A, Ghavamzadeh A, Forooshani RS (2023). Novel Delivery of Sorafenib by Natural Killer Cell-Derived Exosomes-Enhanced Apoptosis in Triple-Negative Breast Cancer. Nanomedicine, 18(5), 437-453. |
Chicago | Hashemi ZS, Ghavami M, Kiaie SH, Mohammadi F, Barough MS, Khalili S, Hosseinifarjam Z, et al.. "Novel Delivery of Sorafenib by Natural Killer Cell-Derived Exosomes-Enhanced Apoptosis in Triple-Negative Breast Cancer." Nanomedicine 18, no. 5 (2023): 437-453. |
Harvard | Hashemi ZS et al. (2023) 'Novel Delivery of Sorafenib by Natural Killer Cell-Derived Exosomes-Enhanced Apoptosis in Triple-Negative Breast Cancer', Nanomedicine, 18(5), pp. 437-453. |
Vancouver | Hashemi ZS, Ghavami M, Kiaie SH, Mohammadi F, Barough MS, Khalili S, et al.. Novel Delivery of Sorafenib by Natural Killer Cell-Derived Exosomes-Enhanced Apoptosis in Triple-Negative Breast Cancer. Nanomedicine. 2023;18(5):437-453. |
BibTex | @article{ author = {Hashemi ZS and Ghavami M and Kiaie SH and Mohammadi F and Barough MS and Khalili S and Hosseinifarjam Z and Mossahebimohammadi M and Sheidary A and Ghavamzadeh A and Forooshani RS}, title = {Novel Delivery of Sorafenib by Natural Killer Cell-Derived Exosomes-Enhanced Apoptosis in Triple-Negative Breast Cancer}, journal = {Nanomedicine}, volume = {18}, number = {5}, pages = {437-453}, year = {2023} } |
RIS | TY - JOUR AU - Hashemi ZS AU - Ghavami M AU - Kiaie SH AU - Mohammadi F AU - Barough MS AU - Khalili S AU - Hosseinifarjam Z AU - Mossahebimohammadi M AU - Sheidary A AU - Ghavamzadeh A AU - Forooshani RS TI - Novel Delivery of Sorafenib by Natural Killer Cell-Derived Exosomes-Enhanced Apoptosis in Triple-Negative Breast Cancer JO - Nanomedicine VL - 18 IS - 5 SP - 437 EP - 453 PY - 2023 ER - |